NovaBay Pharmaceuticals Completes Asset Sale Agreement
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has taken a significant step by finalizing a definitive asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC. This agreement involves the sale of its Avenova brand and its associated assets for $9.5 million in cash. The board of directors has approved this move and is currently awaiting necessary closing conditions, including approval from stockholders.
Overview of the Avenova Brand
Avenova, one of NovaBay's flagship products, especially its Lid & Lash Cleansing Spray, is well-known for effectively treating blepharitis and dry eye disease. Manufactured in the U.S. using NovaBay's patented hypochlorous acid formula, Eyecare professionals often recommend Avenova to promote better ocular health.
Impact of the Asset Sale
Justin Hall, the CEO of NovaBay, shared his optimistic views on the sale, highlighting how it enables stockholders to recognize the value created through the Avenova brand over the past ten years. He expressed confidence in PRN's established reputation in the eyecare industry, along with its extensive network that includes over 5,000 eyecare professionals. Hall believes that with PRN's resources and expertise, the Avenova brand is set to continue its success.
The Role of Stockholders
After thorough evaluations with independent financial and legal advisors, the board concluded that selling the assets serves the best interests of the company and its stockholders. To complete the transaction, approval from stockholders holding at least a majority of the shares is essential. A proxy solicitation will be organized to gather votes on this matter.
Looking Ahead for NovaBay
This asset sale marks a crucial juncture for NovaBay while aligning with the company's overall strategy to invest in product development, all while ensuring that Avenova continues enhancing patient care under PRN's direction. The transition is expected to be completed by the fourth quarter of 2024, paving the way for Avenova to achieve new milestones.
The Future of Avenova
With the sale set to complete, Avenova is positioned to utilize PRN’s market strength and distribution channels to broaden its reach. This collaboration holds promise for both parties—creating opportunities for continued growth and innovation in eyecare products. The expert leadership of PRN is anticipated to be instrumental in effectively promoting Avenova.
About NovaBay Pharmaceuticals
Dedicated to advancing ocular health, NovaBay Pharmaceuticals, Inc. works tirelessly to enhance the quality of life for those dealing with conditions such as dry eye and blepharitis. The company emphasizes innovative product development and strategic alliances to strengthen its market presence.
Frequently Asked Questions
What is the primary focus of NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals is dedicated to developing innovative products for ocular health, especially through the Avenova brand.
Who is acquiring the Avenova assets?
The Avenova assets are being acquired by PRN Physician Recommended Nutriceuticals, LLC.
What is the sale price of Avenova?
The sale price for the Avenova assets is set at $9.5 million in cash.
When is the sale expected to be finalized?
The transaction is projected to be finalized in the fourth quarter of 2024, contingent upon stockholder approval.
How will this sale influence NovaBay's future?
This sale is designed to allow NovaBay to concentrate on expanding its other product lines while ensuring Avenova continues to grow under new management.
